Development of a tetracycline-inducible programmed ribosomal frameshifting platform for sensitive regulation of mammalian gene expression
Nucleic Acids Research · 05.05.2026 · 54 (9)
DOI: 10.1093/nar/gkag426 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 08.05.2026. Verfasst von Sıla Köse und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Konstanz, Konstanz 78457, Germany. Hauptthemen laut MEDLINE: Riboswitch, Tetracycline, Frameshifting, Ribosomal, Gene Expression Regulation. Die Arbeit nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Collaborative Research Center, Chemical and Biological Principles of Cellular Proteostasis.
Abstract (Originalsprache)
Developing engineered genetic switches that can respond to specific stimuli in mammalian systems has great potential to advance next-generation therapies. This study introduces a novel tetracycline-inducible artificial riboswitch that regulates gene expression at the translational level via a modified −1 programmed ribosomal frameshifting (−1 PRF) platform. Our dose-response analysis reveals an EC50 of 0.41 μM, indicating exceptional sensitivity compared to other tetracycline-dependent artificial riboswitches developed for mammalian applications. By varying the precise spacing and composition of the tetracycline aptamer as the stimulatory structure on the −1 PRF platform, a series of switches has been constructed that enable robust induction of gene expression upon ligand addition. To attain a translational gene control platform with broader applicability, we developed a concept that allows it to be integrated upstream of a gene of interest (GOI), enabling precise control without requiring extensive re-engineering and expressing the GOI as a fusion protein. We validate the platform’s effectiveness in several genetic contexts, confirming its modularity. As optimization efforts continue to develop artificial riboswitches with optimized properties in mammalian systems, our findings contribute to the development of highly sensitive and efficient regulatory devices with beneficial characteristics, such as reversibility, modularity, and compatibility with RNA-based delivery therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, University of Konstanz, Konstanz 78457, Germany.
- Konstanz Research School Chemical Biology, University of Konstanz, Konstanz 78457, Germany.
- Clinical Cooperation Unit Virotherapy, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.
- Department of Medical Oncology, Heidelberg University Hospital, National Center for Tumor Diseases, Heidelberg 69120, Germany.
ORCID-Profile: Sıla Köse, Elisabeth Müller, Pierre Gommeringer, Jörg S Hartig
Förderung
- Deutsche Forschungsgemeinschaft
- Collaborative Research Center
- Chemical and Biological Principles of Cellular Proteostasis
- German Cancer Aid
- University of Konstanz
Zitieren
APA
Köse, S., Müller, E., Gommeringer, P., Nettelbeck, D. M., Ungerechts, G., & Hartig, J. S. (2026). Development of a tetracycline-inducible programmed ribosomal frameshifting platform for sensitive regulation of mammalian gene expression. Nucleic Acids Research, 54(9). https://doi.org/10.1093/nar/gkag426
Vancouver
Köse S, Müller E, Gommeringer P, Nettelbeck DM, Ungerechts G, Hartig JS. Development of a tetracycline-inducible programmed ribosomal frameshifting platform for sensitive regulation of mammalian gene expression. Nucleic Acids Research. 2026;54(9). doi:10.1093/nar/gkag426
BibTeX
@article{Kse2026,
author = {Köse, Sıla and Müller, Elisabeth and Gommeringer, Pierre and Nettelbeck, Dirk M and Ungerechts, Guy and Hartig, Jörg S},
title = {Development of a tetracycline-inducible programmed ribosomal frameshifting platform for sensitive regulation of mammalian gene expression},
journal = {Nucleic Acids Research},
year = {2026},
volume = {54},
number = {9},
doi = {10.1093/nar/gkag426}
}
EUVIMED